Clinician Scientist in Leukemia

白血病临床科学家

• 批准号: 10566421
• 负责人: GEOFFREY L UY
• 金额: $ 13.28万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-18 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10566421
• 关键词: Biological; Cancer Center; Cessation of life; Clinical; Clinical Research; Clinical Trials; Companions; Conduct Clinical Trials; Disease remission; Elderly; Ensure; Flow Cytometry; Funding; Geriatric Assessment; Goals; Institution; Leadership; Malignant Neoplasms; Measurable; Measures; Molecular; Molecular Abnormality; Myeloproliferative disease; National Cancer Institute; Oncology; Patient Selection; Patients; Physician Executives; Precision Medicine Initiative; Prediction of Response to Therapy; Protocol Compliance; Research; Residual Neoplasm; Scientist; Testing; Underrepresented Minority; Universities; Washington; clinical implementation; health disparity; improved; leukemia; medical schools; novel therapeutics; precision medicine; prognostic significance; programs; social health determinants; targeted treatment; treatment trial

PROJECT SUMMARY / ABSTRACT This project is intended to support the applicant as a clinician-scientist in leukemia at Washington University School of Medicine / Siteman Cancer Center supporting NCI-funded clinical research. As Medical Director for Clinical Research, the applicant will support the implementation of clinical research at the institution by 1) improving operational efficiency, 2) expanding program capabilities, and 3) ensuring protocol compliance to achieve the highest quality conduct of clinical trials that can improve the lives of patients with cancer. The applicant will also provide scientific leadership to NCI-funded research as co-chair of the Leukemia Committee of the Alliance for Clinical Trials in Oncology and the Older AML Clinical Basket for myeloMATCH, the NCI Precision Medicine Initiative in myeloid malignancies. The Leukemia Committee of the Alliance will continue to conduct practice-changing treatment trials and further our understanding of the biological basis of leukemia and its treatment. In addition, the Committee will address health disparities in leukemia by increasing the accrual of underrepresented minorities and assessing the impact of social determinants of health. In older adults with AML, myeloMATCH will test the combination of targeted therapies with hypomethylating agents and venetoclax to improve remission rates and validate the prognostic significance of flow cytometry- based measurable residual disease. A companion geriatric assessment will be implemented across treatment studies to validate measures that predict treatment tolerance and benefit.

项目摘要/摘要 该项目旨在支持申请者成为华盛顿大学白血病的临床科学家。 医学院/西特曼癌症中心支持NCI资助的临床研究。担任医疗总监 临床研究，申请者将在1)之前支持该机构临床研究的实施 提高运营效率，2)扩展计划功能，3)确保协议合规性，以 实现最高质量的临床试验，以改善癌症患者的生活。 申请者还将作为白血病联合主席为NCI资助的研究提供科学领导 肿瘤学临床试验联盟委员会和较老的急性髓细胞白血病临床篮子， NCI在髓系恶性肿瘤中的精准医学倡议。该联盟的白血病委员会将 继续进行改变实践的治疗试验，并进一步了解糖尿病的生物学基础 白血病及其治疗。此外，该委员会将通过增加 代表不足的少数群体的累积情况，以及评估健康的社会决定因素的影响。 在患有AML的老年人中，骨髓MATCH将测试靶向治疗与去甲基化的组合 药物和万乃馨以提高缓解率并验证流式细胞术的预后意义- 基于可测量的残留病。将在整个治疗过程中实施伴随的老年评估 对预测治疗耐受性和益处的措施进行验证的研究。